AU624487B2 - Method for enhancing glycoprotein stability - Google Patents

Method for enhancing glycoprotein stability

Info

Publication number
AU624487B2
AU624487B2 AU51336/90A AU5133690A AU624487B2 AU 624487 B2 AU624487 B2 AU 624487B2 AU 51336/90 A AU51336/90 A AU 51336/90A AU 5133690 A AU5133690 A AU 5133690A AU 624487 B2 AU624487 B2 AU 624487B2
Authority
AU
Australia
Prior art keywords
enhancing
glycoprotein
stability
glycoprotein stability
enhancing glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU51336/90A
Other versions
AU5133690A (en
Inventor
Michel Louis Eugene Bergh
S. Catherine Hubbard
James R. Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of AU5133690A publication Critical patent/AU5133690A/en
Application granted granted Critical
Publication of AU624487B2 publication Critical patent/AU624487B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
AU51336/90A 1986-03-07 1990-03-14 Method for enhancing glycoprotein stability Ceased AU624487B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU597574 1986-03-07
PCT/US1986/000495 WO1987005330A1 (en) 1986-03-07 1986-03-07 Method for enhancing glycoprotein stability

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU56271/86A Division AU597574B2 (en) 1986-03-07 1986-03-07 Method for enhancing glycoprotein stability

Publications (2)

Publication Number Publication Date
AU5133690A AU5133690A (en) 1990-08-23
AU624487B2 true AU624487B2 (en) 1992-06-11

Family

ID=22195409

Family Applications (2)

Application Number Title Priority Date Filing Date
AU56271/86A Ceased AU597574B2 (en) 1986-03-07 1986-03-07 Method for enhancing glycoprotein stability
AU51336/90A Ceased AU624487B2 (en) 1986-03-07 1990-03-14 Method for enhancing glycoprotein stability

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU56271/86A Ceased AU597574B2 (en) 1986-03-07 1986-03-07 Method for enhancing glycoprotein stability

Country Status (5)

Country Link
EP (1) EP0272253A4 (en)
JP (1) JPS63502716A (en)
AU (2) AU597574B2 (en)
DK (1) DK583087D0 (en)
WO (1) WO1987005330A1 (en)

Families Citing this family (551)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
WO1989007641A1 (en) * 1988-02-10 1989-08-24 Genzyme Corporation Enhancement of the therapeutic properties of glycoprotein
DE3927801A1 (en) * 1989-08-23 1991-02-28 Hoechst Ag PROCESS FOR ENZYMATIC SYNTHESIS OF GALACTOSYLATED GLYCOPROTEIN COMPONENTS
AU675209B2 (en) 1991-10-15 1997-01-30 Scripps Research Institute, The Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
US6319695B1 (en) * 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
SK284191B6 (en) 1995-02-24 2004-10-05 Genentech, Inc. Human DNASE I variants
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
EP1500702A1 (en) 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
WO1998033924A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1003856A1 (en) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
AU740227B2 (en) 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
EP1659131B1 (en) 1997-09-17 2009-11-04 Genentech, Inc. Polypeptides and nucleic acids encoding the same
ES2306480T3 (en) 1997-09-18 2008-11-01 Genentech, Inc. DCR3 POLYPEPTIDE, A TNFR HOMOLOGIST.
EP1967587A1 (en) 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
EP2014770A3 (en) 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
ES2316173T3 (en) 1997-10-29 2009-04-01 Genentech, Inc. INDUCIBLE GENES BY WNT-1.
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
DE69840105D1 (en) 1997-11-21 2008-11-20 Genentech Inc PLATE-SPECIFIC ANTIGENES AND THEIR PHARMACEUTICAL USE
DE69939732D1 (en) 1998-01-15 2008-11-27 Genentech Inc APO-2 LIGAND
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
IL138488A0 (en) 1998-03-17 2001-10-31 Genentech Inc Polypeptides homologous to vegf and bmp1
ES2292242T5 (en) 1998-05-15 2011-05-04 Genentech, Inc. THERAPEUTIC USES OF IL-17 HOMOLOGICAL POLYPEPTIDES.
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
CA2354027A1 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2496312A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
DK1897945T3 (en) 1999-12-23 2012-05-07 Genentech Inc IL-17 homologous polypeptides and therapeutic uses thereof.
WO2001051510A2 (en) 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
AU785055B2 (en) 2000-01-13 2006-09-07 Genentech Inc. Novel stra6 polypeptides
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2648048A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6576452B1 (en) 2000-10-04 2003-06-10 Genencor International, Inc. 2,5-diketo-L-gluconic acid reductases and methods of use
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030232334A1 (en) 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
YU48703A (en) 2001-02-27 2006-05-25 Maxygen Aps New interferon beta-like molecules
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
MXPA03011985A (en) 2001-06-20 2004-03-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
WO2003020892A2 (en) 2001-08-29 2003-03-13 Genentech, Inc. Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
ES2390531T3 (en) 2001-09-18 2012-11-13 Genentech, Inc. Compositions and procedures for the diagnosis and treatment of tumor
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
DK1578771T3 (en) 2001-10-10 2013-06-10 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
EP2322229B1 (en) 2001-10-10 2016-12-21 Novo Nordisk A/S Remodeling and glycoconjugation of Factor IX
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
WO2003046150A2 (en) 2001-11-28 2003-06-05 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003072714A2 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc Compositions and methods for the treatment of immune related diseases
EP1485477B1 (en) 2002-02-25 2009-05-13 Genentech, Inc. Novel type-1 cytokine receptor glm-r
EP2093233A1 (en) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Novel compositions and methods in cancer
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP1553912A4 (en) 2002-06-07 2007-08-08 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006515159A (en) 2002-08-02 2006-05-25 ワイエス MK2 interacting protein
CN101792749B (en) 2002-08-12 2012-09-05 金克克国际有限公司 Mutant colibacillus appa phytase enzymes
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003276874B2 (en) 2002-09-11 2009-09-03 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2503748A1 (en) 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
JP2011516026A (en) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
TWI330641B (en) 2002-12-24 2010-09-21 Yasuhiro Kajihara Sugar chain asparagine derivatives
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
FR2851471B1 (en) * 2003-02-24 2006-07-28 Synt Em COMPOUNDS COMPRISING AT LEAST ONE ACTIVE SUBSTANCE AND AT LEAST ONE VECTOR CONNECTED BY A BINDING AGENT, USES THEREOF AND THE BINDING AGENTS
MXPA05009743A (en) 2003-03-12 2006-03-09 Genentech Inc Use of bv8 and/or eg-vegf to promote hematopoiesis.
NZ542306A (en) 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
ES2383014T3 (en) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor I and their uses
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP1624847B1 (en) 2003-05-09 2012-01-04 BioGeneriX AG Compositions and methods for the preparation of human growth hormone glycosylation mutants
RU2005136988A (en) 2003-05-30 2006-06-10 Дженентек, Инк. (Us) ANTIBODY TREATMENT AGAINST VEGF
KR100835786B1 (en) 2003-07-08 2008-06-09 제넨테크, 인크. - il-17a/f heterologous polypeptides and therapeutic uses thereof
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP2327723A3 (en) 2003-10-10 2012-06-27 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
JP4901478B2 (en) 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド Compositions and methods for the treatment of tumors of hematopoietic origin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US7405198B2 (en) 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
PT2311873T (en) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc M-csf-specific monoclonal antibody and uses thereof
EP1765853B1 (en) 2004-01-08 2015-10-28 ratiopharm GmbH O-linked glycosylation of G-CSF peptides
CA2561533C (en) 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
RU2006138181A (en) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) O-RELATED Glycoforms of Polypeptides and a Method for Their Production
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
ES2710048T3 (en) 2004-07-23 2019-04-22 Acceleron Pharma Inc Antagonist antibodies to the ActRII receptor
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DE602005022928D1 (en) 2004-11-30 2010-09-23 Abgenix Inc ANTIBODIES AGAINST GPNMB AND ITS USES
ES2449195T3 (en) 2005-01-10 2014-03-18 Ratiopharm Gmbh Glycopegylated granulocyte colony stimulating factor
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
KR101289537B1 (en) 2005-02-15 2013-07-31 듀크 유니버시티 Anti-cd19 antibodies and uses in oncology
US9820986B2 (en) 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP2008535853A (en) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Cancer-related genes
CA2604885A1 (en) 2005-04-07 2006-10-19 Guoying Yu Cacna1e in cancer diagnosis, detection and treatment
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
SG162728A1 (en) 2005-05-27 2010-07-29 Biogen Idec Inc Tweak binding antibodies
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US8105585B2 (en) 2005-08-24 2012-01-31 The Rockefeller Universtiy Ply-GBS mutant lysins
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007056858A1 (en) 2005-11-18 2007-05-24 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
KR101557375B1 (en) 2005-11-23 2015-10-08 악셀레론 파마 인코포레이티드 Activin-actrπa antagonists and uses for promoting bone growth
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
CN101626783A (en) 2006-08-04 2010-01-13 诺华有限公司 EPHB3-specific antibody and its application
EP3415532A1 (en) 2006-08-18 2018-12-19 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
US8349801B2 (en) 2006-09-18 2013-01-08 Compugen Ltd. Peptide ligands for G-protein coupled receptors
BRPI0717512A2 (en) 2006-09-29 2013-11-19 Hoffmann La Roche CCR5 ANTIBODIES AND USES OF THE SAME
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
MX2009003470A (en) 2006-10-04 2009-04-14 Novo Nordisk As Glycerol linked pegylated sugars and glycopeptides.
US20080254512A1 (en) 2006-11-02 2008-10-16 Capon Daniel J Hybrid immunoglobulins with moving parts
CN111518218A (en) 2006-11-02 2020-08-11 阿塞勒隆制药公司 ALK1 receptor and ligand antagonists and uses thereof
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
TWI432449B (en) 2007-02-02 2014-04-01 Acceleron Pharma Inc Variants derived from actriib and uses therefor
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
KR101508397B1 (en) 2007-02-22 2015-04-08 제넨테크, 인크. Methods for detecting inflammatory bowel disease
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
CA2693651A1 (en) 2007-07-12 2009-01-15 Ronen Shemesh Bioactive peptides and method of using same
US9845355B2 (en) 2007-07-16 2017-12-19 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
PL2474557T3 (en) 2007-07-16 2015-02-27 Genentech Inc Anti-CD79b antibodies and immunoconjugates and methods of use
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
ES2672769T3 (en) 2007-08-29 2018-06-18 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
DK2769729T3 (en) 2007-09-04 2019-04-23 Compugen Ltd POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2558155T3 (en) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compounds showing glucacon antagonist activity and GLP-1 agonist
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
EP2238165B1 (en) 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
JP5701064B2 (en) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド Ferroportin antibody and method of use thereof
ES2618292T3 (en) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Antibodies against and use of human CD39 to inhibit the activity of regulatory T cells
RU2553566C2 (en) 2008-01-31 2015-06-20 Дженентек, Инк. ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM
KR101582841B1 (en) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 Conjugated factor viii molecules
CN104655854A (en) 2008-04-09 2015-05-27 健泰科生物技术公司 Novel compositions and methods for the treatment of immune related diseases
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
CN105963695A (en) 2008-05-02 2016-09-28 阿塞勒隆制药公司 Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
TWI541023B (en) 2008-06-17 2016-07-11 印第安納大學科技研究公司 Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
EA020326B9 (en) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Gip-based mixed agonists for treatment of metabolic disorders and obesity
CL2009001424A1 (en) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Glucagon-like peptide; dimer comprising two of said peptides; pharmaceutical composition comprising it; and its use to treat diabetes or induce weight loss.
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
TW201803586A (en) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 Use of GDF traps to increase red blood cell levels
CN102282172B (en) 2008-09-07 2014-02-19 台湾醣联生技医药股份有限公司 Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US8481033B2 (en) 2008-10-07 2013-07-09 INSERM (Institute National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
AU2009312532B2 (en) 2008-11-06 2013-05-16 Ichnos Sciences SA Treatment with anti-alpha2 integrin antibodies
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
EP2865689A1 (en) 2008-12-08 2015-04-29 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CA2747499A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP5755566B2 (en) 2008-12-19 2015-07-29 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Amide insulin prodrug
JO3382B1 (en) 2008-12-23 2019-03-13 Amgen Inc Human cgrp receptor binding antibodies
US8952130B2 (en) 2009-02-24 2015-02-10 The Salk Institute For Biological Studies Designer ligands of TGF-β superfamily
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
JP2012521197A (en) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Carrier immunoglobulin and use thereof
CA2756206A1 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
EP3702001A1 (en) 2009-03-30 2020-09-02 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
NZ595574A (en) 2009-04-01 2013-11-29 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
US8580732B2 (en) 2009-04-07 2013-11-12 Duke University Peptide therapy for hyperglycemia
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
BRPI1010587A2 (en) 2009-06-08 2019-04-09 Acceleron Pharma Inc. Methods to Increase Thermogenic Adipocytes
ES2836534T3 (en) 2009-06-12 2021-06-25 Acceleron Pharma Inc Truncated ActRIIB-Fc fusion proteins
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
NZ623113A (en) 2009-08-13 2015-10-30 Acceleron Pharma Inc Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IN2012DN02766A (en) 2009-09-09 2015-09-18 Acceleron Pharma Inc
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN102656266B (en) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 There is the chimeric fibroblast growth factor of the receptor-specific of change
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
AU2010311567B2 (en) 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Human il-23 antigen binding proteins
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
EP3818988A1 (en) 2009-11-03 2021-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (en) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド ACTRIIB protein and its variants and uses thereof for utrophin induction for the treatment of muscular dystrophy
CA2781532A1 (en) 2009-11-20 2011-05-26 Amgen Inc. Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
PE20121584A1 (en) 2009-11-30 2012-11-29 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
RU2012136450A (en) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
KR20130004579A (en) 2010-02-23 2013-01-11 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
EP3590966A1 (en) 2010-02-23 2020-01-08 Sanofi Anti-alpha2 integrin antibodies and their uses
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CN103119054B (en) 2010-03-26 2017-01-18 达特茅斯大学理事会 VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
CN107090045A (en) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 Composition and method for tumor diagnosis and therapy
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
JP2013530187A (en) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Compositions and methods for treating inflammatory diseases.
RU2580317C2 (en) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Peptide pro-drugs of amide glucagon superfamily
JP5912112B2 (en) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Amide insulin prodrug
EP3202415B1 (en) 2010-06-30 2021-12-08 Compugen Ltd. Fusion protein comprising a c1orf32 polypeptide and one or more domains of an immunoglobulin heavy chain constant region for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders.
WO2012010696A1 (en) 2010-07-23 2012-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
US8993727B2 (en) 2010-09-22 2015-03-31 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
TWI537385B (en) 2010-11-04 2016-06-11 中央研究院 Methods for producing virus particles with simplified glycosylation of surface proteins
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
SG191194A1 (en) 2010-12-22 2013-07-31 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
AR085911A1 (en) 2011-03-16 2013-11-06 Sanofi Sa SAFE THERAPEUTIC DOSE OF A SIMILAR PROTEIN TO AN ANTIBODY WITH VUAL REGION
EP2691419B1 (en) 2011-03-31 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos and uses thereof
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN108341863A (en) 2011-04-20 2018-07-31 阿塞勒隆制药公司 Endoglin polypeptide and application thereof
WO2012156532A1 (en) 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
SG10201902706VA (en) 2011-06-03 2019-04-29 Xoma Technology Ltd Antibodies specific for tgf-beta
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
JP6179864B2 (en) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon / GLP-1 receptor co-agonist
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
AU2012279237B2 (en) 2011-07-01 2016-09-29 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
US8987422B2 (en) 2011-09-22 2015-03-24 Amgen Inc. CD27L antigen binding proteins
AU2012318306A1 (en) 2011-10-06 2014-04-24 The Board Of Trustees Of The University Of Illinois Myosin binding protein- C for use in methods relating to diastolic heart failure
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
DK2766392T3 (en) 2011-10-10 2019-10-07 Xencor Inc PROCEDURE FOR CLEANING ANTIBODIES
BR112014009528B1 (en) 2011-10-17 2020-12-29 Acceleron Pharma, Inc. uses of actriib polypeptides for the manufacture of a drug to treat ineffective erythropoiesis
BR112014007124A2 (en) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamily of gluxagon peptides that exhibit glucocorticoid receptor activity
JP6635655B2 (en) 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド Human LCAT antigen binding proteins and their use in therapy
US20150045301A1 (en) 2011-12-16 2015-02-12 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
JP6392123B2 (en) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ CTP-based insulin analog for diabetes treatment
IN2014KN00848A (en) 2012-02-01 2015-10-02 Compugen Ltd
MX2014009277A (en) 2012-02-02 2015-03-03 Acceleron Pharma Inc Alk1 antagonists and their uses in treating renal cell carcinoma.
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
PL3431492T3 (en) 2012-04-27 2021-07-05 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
UY34813A (en) 2012-05-18 2013-11-29 Amgen Inc ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
KR20150023729A (en) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
BR112014031671A2 (en) 2012-06-21 2018-08-07 Hoffmann La Roche glucagon analogs exhibiting gip receptor activity
MX2014015558A (en) 2012-06-21 2015-03-05 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity.
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
EP3613765A1 (en) 2012-08-03 2020-02-26 Dana-Farber Cancer Institute, Inc. Antibody against repulsive guidance molecule b (rgmb)
ES2684552T3 (en) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Antibodies directed against ICOS to treat graft versus host disease
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
EP2912462B1 (en) 2012-10-24 2019-08-07 Celgene Corporation Biomarker for use in treating anemia
MX366336B (en) 2012-11-02 2019-07-05 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders.
PT2922875T (en) 2012-11-20 2017-05-31 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
ES2828505T3 (en) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Compositions and methods for the treatment of metabolic disorders and diseases
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
EP3686218A1 (en) 2012-12-10 2020-07-29 Biogen MA Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
SG11201504920SA (en) 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
RU2675514C2 (en) 2012-12-27 2018-12-19 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
EP3888671A3 (en) 2013-03-11 2022-01-05 Amgen Inc. Protein formulations
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
WO2014145174A1 (en) 2013-03-15 2014-09-18 Biological Mimetics, Inc. Immunogenic human rhinovirus (hrv) compositions
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
HUE045859T2 (en) 2013-03-15 2020-01-28 Amgen Res Munich Gmbh Single chain binding molecules comprising n-terminal abp
PE20151673A1 (en) 2013-03-15 2015-11-27 Genentech Inc IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014144911A2 (en) 2013-03-15 2014-09-18 Capon Daniel J Hybrid immunoglobulin containing non-peptidyl linkage
WO2014151680A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
AU2014228924B2 (en) 2013-03-15 2019-04-18 Amgen Inc. Human PAC1 antibodies
EP2968508B1 (en) 2013-03-15 2022-04-27 Sanofi Pasteur Biologics, LLC Antibodies against clostridium difficile toxins and methods of using the same
KR102561553B1 (en) 2013-03-15 2023-07-31 젠코어 인코포레이티드 Heterodimeric proteins
CN105263514B (en) 2013-03-15 2019-04-26 本质生命科学有限公司 Anti- hepcidin antibody and application thereof
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
MX351127B (en) 2013-05-30 2017-10-03 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins.
PL3036320T3 (en) 2013-08-19 2021-11-02 Biogen Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
AR097648A1 (en) 2013-09-13 2016-04-06 Amgen Inc COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
KR102354787B1 (en) 2013-10-25 2022-01-24 악셀레론 파마 인코포레이티드 Endoglin peptides to treat fibrotic diseases
ES2759252T3 (en) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Nuclease-albumin fusions and therapeutic methods
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
JP2017500017A (en) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
EP3087098B1 (en) 2013-12-24 2020-04-08 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR102472816B1 (en) 2014-02-20 2022-11-30 알러간, 인코포레이티드 Complement component c5 antibodies
BR112016019825A2 (en) 2014-02-27 2017-10-17 Allergan Inc complement factor bb antibodies
CA2941697A1 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for modifying the immune response
LT3701971T (en) 2014-03-14 2023-01-10 Biomolecular Holdings Llc Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage
US11124760B2 (en) 2014-03-24 2021-09-21 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
WO2015158851A1 (en) 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3020063A1 (en) 2014-04-16 2015-10-23 Gamamabs Pharma ANTI-HER4 HUMAN ANTIBODY
US10654926B2 (en) 2014-05-02 2020-05-19 Medimmune Limited P2X4 antibodies and uses thereof
AU2015269333B2 (en) 2014-06-04 2020-05-07 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
CN107073109B (en) 2014-06-11 2021-08-06 凯西·A·格林 Use of VISTA agonists and antagonists to inhibit or enhance humoral immunity
MX2017000319A (en) 2014-07-09 2017-04-27 Midori Usa Inc Oligosaccharide compositions and methods for producing thereof.
AR101400A1 (en) 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh INDIVIDUAL CHAIN INDIVIDUAL CHAIN ANTIBODY CONSTRUCTION WITH IMPROVED FABRIC DISTRIBUTION
TW201609812A (en) 2014-07-31 2016-03-16 安美基研究（慕尼黑）公司 Optimized cross-species specific bispecific single chain antibody constructs
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
EP3185885B1 (en) 2014-08-26 2020-08-19 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
EP3575316A1 (en) 2014-08-27 2019-12-04 Amgen, Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MY180054A (en) 2014-09-30 2020-11-20 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
MA41685A (en) 2014-10-17 2017-08-22 Biogen Ma Inc COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS
AU2015335029B2 (en) 2014-10-24 2021-09-23 Astrazeneca Ab Combination
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
CU24597B1 (en) 2014-11-26 2022-05-11 Xencor Inc HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20
TN2017000222A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MD4801C1 (en) 2014-12-03 2022-10-31 Celgene Corporation Activin-ActRII antagonists and uses for treating myelodysplastic syndromes
EP3226900A4 (en) 2014-12-05 2018-09-19 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
RS60916B1 (en) 2015-01-23 2020-11-30 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
BR112017015944B1 (en) 2015-01-26 2022-03-22 Cadena Bio, Inc Animal feed composition, animal feed premix, use and method for producing an animal feed composition
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
UA126270C2 (en) 2015-04-10 2022-09-14 Емджен Інк. Interleukin-2 muteins for the expansion of t-regulatory cells
CN116063541A (en) 2015-04-17 2023-05-05 安进研发（慕尼黑）股份有限公司 Bispecific antibody constructs for CDH3 and CD3
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017009712A1 (en) 2015-07-13 2017-01-19 Compugen Ltd. Hide1 compositions and methods
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
JOP20170017B1 (en) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh Pharmaceutical composition comprising bispecific antibody constructs
WO2017134158A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
DK3411402T3 (en) 2016-02-03 2022-02-07 Amgen Res Munich Gmbh BCMA AND CD3 BISPECIFIC T-CELL INVOLVING ANTIBODY CONSTRUCTIONS
MX2018009800A (en) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies.
EP3442579A4 (en) 2016-04-15 2019-12-18 Immunext Inc. Anti-human vista antibodies and use thereof
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
JP7422480B2 (en) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド Interleukin-2 mutant protein for regulatory T cell proliferation
EP3464337A4 (en) 2016-05-31 2019-12-18 Mogam Institute for Biomedical Research Ab6 family designer ligands of tgf-beta superfamily
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
MA45554A (en) 2016-07-01 2019-05-08 Resolve Therapeutics Llc OPTIMIZED BINUCLEASE FUSIONS.
CN117330747A (en) 2016-07-15 2024-01-02 武田药品工业株式会社 Methods and materials for assessing response to plasmacytoid and plasma cell depleting therapies
TWI790206B (en) 2016-07-18 2023-01-21 法商賽諾菲公司 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
WO2018022479A1 (en) 2016-07-25 2018-02-01 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
JP7148493B2 (en) 2016-08-01 2022-10-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2019531070A (en) 2016-09-15 2019-10-31 アクセレロン ファーマ インコーポレーテッド Twisted gas torsion polypeptide and uses thereof
WO2018064098A1 (en) 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides
MX2019003543A (en) 2016-09-28 2019-06-17 Xoma Us Llc Antibodies that bind interleukin-2 and uses thereof.
JP7142630B2 (en) 2016-10-14 2022-09-27 ゼンコア インコーポレイテッド IL15/IL15Rα heterodimeric FC-fusion protein
TW202300515A (en) 2016-10-20 2023-01-01 法商賽諾菲公司 Anti-chikv antibodies and uses thereof
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
ES2916217T3 (en) 2017-01-05 2022-06-29 Kahr Medical Ltd A SIRP1 ALPHA-41BBL fusion protein and methods of using the same
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018156892A1 (en) 2017-02-23 2018-08-30 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
MX2019010848A (en) 2017-03-16 2019-10-30 Innate Pharma Compositions and methods for treating cancer.
EP3615569A1 (en) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2018204594A1 (en) 2017-05-04 2018-11-08 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
UY37726A (en) 2017-05-05 2018-11-30 Amgen Inc PHARMACEUTICAL COMPOSITION THAT INCLUDES BISPECTIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
CN111094334A (en) 2017-07-19 2020-05-01 美国卫生与公众服务部 Antibodies and methods for diagnosis and treatment of hepatitis B virus infection
RS63101B1 (en) 2017-08-03 2022-04-29 Amgen Inc Interleukin-21 muteins and methods of treatment
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
MX2020002070A (en) 2017-08-22 2020-03-24 Sanabio Llc Soluble interferon receptors and uses thereof.
TWI731264B (en) 2017-09-08 2021-06-21 美商安進公司 Inhibitors of kras g12c and methods of using the same
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
EP3737694B1 (en) 2018-01-12 2023-03-01 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
RU2020127792A (en) 2018-01-26 2022-02-28 Дженентек, Инк. IL-22-Fc fusion proteins AND METHODS OF APPLICATION
LT3743088T (en) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc compositions and methods of use
AU2019222705A1 (en) 2018-02-14 2020-10-01 Horizon Therapeutics Ireland Dac Antibodies to feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
SG11202007694UA (en) 2018-02-21 2020-09-29 Genentech Inc DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
US20210171610A1 (en) 2018-05-02 2021-06-10 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
CA3099893A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
CN112584859A (en) 2018-07-02 2021-03-30 美国安进公司 anti-STEAP 1 antigen binding proteins
CN112543773A (en) 2018-07-11 2021-03-23 卡尔医学有限公司 SIRP alpha-4-1 BBL variant fusion proteins and methods of use thereof
MX2021001221A (en) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3.
KR20210042117A (en) 2018-08-03 2021-04-16 암젠 리서치 (뮌헨) 게엠베하 Antibody constructs against CLDN18.2 and CD3
CN113166241A (en) 2018-08-16 2021-07-23 约翰霍普金斯大学 Human ZNT8 antibodies
CN113195523A (en) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12 heterodimer Fc fusion proteins
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
CN113597319A (en) 2019-01-04 2021-11-02 分解治疗有限责任公司 Treatment of xerosis with nuclease fusion proteins
EP3917944A1 (en) 2019-01-28 2021-12-08 Cohbar Inc. Therapeutic peptides
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
US20220080053A1 (en) 2019-02-07 2022-03-17 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
KR20210136014A (en) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 Compositions, methods and uses thereof containing antibody-TLR agonist conjugates
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
CA3131705A1 (en) 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use
MX2021012160A (en) 2019-04-08 2022-01-06 Biogen Ma Inc Anti-integrin antibodies and uses thereof.
BR112021019128A2 (en) 2019-04-09 2022-01-04 Abcuro Inc Killer cell lectin-like receptor (klrg1) member 1 subfamily depleting antibodies
AU2020290573A1 (en) 2019-06-13 2021-11-04 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
US20220267409A1 (en) 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
JP2022543259A (en) 2019-08-02 2022-10-11 オレガ・バイオテック Novel IL-17B antibody
CA3150441A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
AU2020407208A1 (en) 2019-12-17 2022-06-02 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
WO2021144020A1 (en) 2020-01-15 2021-07-22 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
US20230146593A1 (en) 2020-03-12 2023-05-11 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
EP4169949A1 (en) 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38 antibody and use thereof
CA3165342A1 (en) 2020-06-29 2022-01-06 James Arthur Posada Treatment of sjogren's syndrome with nuclease fusion proteins
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
JP2023540732A (en) 2020-09-04 2023-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-CEACAM5 antibodies and conjugates and uses thereof
EP4240767A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Polypeptide constructs binding to cd3
EP4240407A1 (en) 2020-11-06 2023-09-13 Amgen Inc. Antigen binding domain with reduced clipping rate
KR20230098334A (en) 2020-11-06 2023-07-03 암젠 리서치 (뮌헨) 게엠베하 Polypeptide constructs that selectively bind to CLDN6 and CD3
CN116323671A (en) 2020-11-06 2023-06-23 安进公司 Multi-targeting bispecific antigen binding molecules with increased selectivity
EP4281187A1 (en) 2021-01-20 2023-11-29 Bioentre LLC Ctla4-binding proteins and methods of treating cancer
WO2022192403A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (en) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Heterodimeric antibodies binding to CD3 and GPC3
JP2024513376A (en) 2021-04-02 2024-03-25 アムジエン・インコーポレーテツド MAGEB2 binding construct
KR20240004342A (en) 2021-04-03 2024-01-11 암브룩스, 인코포레이티드 Anti-HER2 antibody-drug conjugates and uses thereof
IL307672A (en) 2021-05-06 2023-12-01 Amgen Res Munich Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
AU2022320627A1 (en) 2021-07-26 2024-02-08 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023099683A1 (en) 2021-12-02 2023-06-08 Sanofi Cea assay for patient selection in cancer therapy
WO2023099682A1 (en) 2021-12-02 2023-06-08 Sanofi Ceacam5 adc–anti-pd1/pd-l1 combination therapy
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
TW202346354A (en) 2022-03-09 2023-12-01 德商馬克專利公司 Anti-ceacam5 antibodies and conjugates and uses thereof
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
TW202346368A (en) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847890A (en) * 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins

Also Published As

Publication number Publication date
AU597574B2 (en) 1990-06-07
DK583087A (en) 1987-11-06
DK583087D0 (en) 1987-11-06
EP0272253A1 (en) 1988-06-29
JPS63502716A (en) 1988-10-13
EP0272253A4 (en) 1990-02-05
WO1987005330A1 (en) 1987-09-11
AU5627186A (en) 1987-09-28
AU5133690A (en) 1990-08-23

Similar Documents

Publication Publication Date Title
AU624487B2 (en) Method for enhancing glycoprotein stability
GB8624513D0 (en) Single point bonding method
AU591007B2 (en) 3-aryloxy-3-substituted propanamines
AU7070887A (en) Method for forming crystals
AU7675787A (en) Laser alignment system
AU6989387A (en) Process for trimerization
AU6808387A (en) Method for recovering gallium
AU593093B2 (en) Radio-direction-finding
AU7520187A (en) Mining method
AU572037B2 (en) Combination weighing method
AU6990587A (en) Urine-receiving system
AU5988990A (en) 3-alkoxy-2-aminopropylamides
AU7388387A (en) Certain 3-benzoyl-4-oxo-2-piperidones
AU8207287A (en) Renin-inhibitors III
AU7388687A (en) Certain substituted 3-amino-2-benzoylcyclohex-2-enones
AU579047B2 (en) Pyridopyrimidinediones
AU585161B2 (en) Micropropogation process
AU8069787A (en) Insect-proofing method
AU591298B2 (en) Improved fusion method
AU7480187A (en) 16alpha-methylation process
AU6961087A (en) Novel method
AU590922B2 (en) Stabilized polyamides
AU592423B2 (en) Pyridylthio-acylanilides
AU7322887A (en) Method for converting substances
AU7948187A (en) Factor IX-peptides